Filing Flows › Comparisons › KRSA vs ABUS
Korsana Biosciences vs Arbutus Biopharma: KRSA and ABUS compared
Korsana Biosciences is the larger company: $1.0M of revenue in its latest quarter (Q4 2025) against $1.0M for Arbutus Biopharma (Q2 2026). Korsana Biosciences is growing faster (-43% against -91% a year earlier). Korsana Biosciences is more profitable, with an operating margin of -81.8% against -588.2%.
Where the money goes: KRSA and ABUS
Korsana Biosciences (KRSA) · Q4 2025
Korsana Biosciences, Q4 2025: revenue $1.0M (-43% year over year), operating margin -81.8%, net loss $799K, operating cash flow −$1.6M. The chart follows the revenue to costs, profit and cash.
Arbutus Biopharma (ABUS) · Q2 2026
Arbutus Biopharma, Q2 2026: revenue $1.0M (-91% year over year), operating margin -588.2%, net loss $5.1M, operating cash flow −$6.0M. The chart follows the revenue to costs, profit and cash.
| Korsana Biosciences (KRSA) | Arbutus Biopharma (ABUS) | |
|---|---|---|
| Latest quarter | Q4 2025 | Q2 2026 |
| Revenue | $1.0M | $1.0M |
| Revenue growth, Y/Y | -43% | -91% |
| Operating margin | -81.8% | -588.2% |
| Net earnings | −$799K | −$5.1M |
| Net margin | -78.0% | -507.2% |
| Operating cash flow | −$1.6M | −$6.0M |
Where the revenue comes from
Arbutus Biopharma
- Revenue from collaborations and licenses: $632K (62%)
- Collaborations and licenses: $202K (20%)
- Non-cash royalty revenue: $180K (18%)
Questions
Which is bigger, Korsana Biosciences or Arbutus Biopharma?
Korsana Biosciences is the larger company: $1.0M of revenue in its latest quarter (Q4 2025) against $1.0M for Arbutus Biopharma (Q2 2026).
Is Korsana Biosciences or Arbutus Biopharma growing faster?
Korsana Biosciences is growing faster (-43% against -91% a year earlier).
Which is more profitable, Korsana Biosciences or Arbutus Biopharma?
Korsana Biosciences is more profitable, with an operating margin of -81.8% against -588.2%.
More: Korsana Biosciences earnings · how Korsana Biosciences makes money · Arbutus Biopharma earnings · how Arbutus Biopharma makes money
From the companies' latest 10-Q, 10-K or earnings release (10-K filed Mar 30, 2026; 10-Q filed Aug 12, 2026). Fiscal quarters can end on different dates. Not investment advice.